Overview

Acute Ischemic Stroke Interventional Study

Status:
Completed

Trial end date:
2021-09-27

Target enrollment:

Participant gender:

Summary

To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a specific focus on hemorrhage, whether clinically symptomatic (NIHSS score + 4 points or death, without other explanation), or seen (excluding other diagnoses) on 24-hour (hr) CT scan, serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs), and medically important events and other safety items including biological and immunological tolerability.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Acticor Biotech

Collaborators:

Axial Biotech, Inc
Orion Corporation, Orion Pharma
QPS

Treatments:

Tissue Plasminogen Activator